Potential new pancreatic cancer treatment safer than standard chemo.
Washington, Nov 3 (ANI): Scientists from Ohio State University Ohio State University, main campus at Columbus; land-grant and state supported; coeducational; chartered 1870, opened 1873 as Ohio Agricultural and Mechanical College, renamed 1878. There are also campuses at Lima, Mansfield, Marion, and Newark. have designed tumour-penetrating microparticles (TPM (1) See TP monitor.
(2) (Transactions Per Minute) The number of transactions processed within one minute. See TPS.
(3) (Trusted Platform M ) may offer treatment hope for those suffering with pancreatic cancer pancreatic cancer
Malignant tumour of the pancreas. Risk factors include smoking, a diet high in fat, exposure to certain industrial products, and diseases such as diabetes and chronic pancreatitis. Pancreatic cancer is more common in men. .
Tiny particles can carry drugs and target cancer cells more effectively and efficiently than the standard form of chemotherapy such as those injected through a vein.
"Pancreatic cancer cells are surrounded by specialized cells that protect them from chemotherapy," said Jessie L.S. Au, Pharm.D., h.D., an AAPS AAPS American Association of Pharmaceutical Scientists
AAPS Association of American Physicians and Surgeons
AAPS Ann Arbor Public Schools
AAPS American Association of Plastic Surgeons
AAPS African Association of Political Science fellow and a distinguished university professor at Ohio State University
"Our goal is to use TPM to pass this barrier and successfully deliver drugs to the tumour cells, which is currently the biggest hurdle a physician faces in pancreatic cancer treatment," Au added.
TPM are designed to treat cancer in the peritoneal cavity peritoneal cavity
The potential space between the parietal and visceral layers of the peritoneum.
peritoneal cavity (per´it . The peritoneal cavity contains organs, including the pancreas.
Au said that TPM releases what the researchers call a "smart bomb" of drugs to create holes in the tumour so TPM can reach tumour cells.
Once inside a tumour, TPM slowly releases drug levels that are sustained over several weeks, targeting both the rapid- and slow-growing tumours.
Because the TPM were designed to move about and reach tumours without being swept away by the lymphatic system lymphatic system (lĭmfăt`ĭk), network of vessels carrying lymph, or tissue-cleansing fluid, from the tissues into the veins of the circulatory system. , they are able to stay in the peritoneal cavity longer and deliver highly concentrated drug doses to the cancer-affected organ.
It is this two-tiered drug attack that is unique in pancreatic cancer treatment.
With just one TPM dose of drugs proving to be equally as effective as multiple injections of chemotherapy, TPM delivers less toxicity to patients, making it a safer option than the standard form of other therapies.
"Based on the encouraging results in mice carrying implants of human pancreatic cancer, we are cautiously optimistic that TPM may provide benefits to patients with this disease," said Dr Ze Lu, principal scientist and project leader.
The findings were presented at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting in Los Angeles ANI).
Copyright 2009 Asian News International The Asian News International (ANI) agency provides multimedia news to China and 50 bureaus in India. It covers virtually all of South Asia since its foundation and presently claims, on its official website, to be the leading South Asia-wide news agency. (ANI) - All Rights Reserved.
Provided by Syndigate.info an Albawaba.com company